Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.